Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemodialysis Catheters: A Randomized, PROBE, Parallel-Grupo Trial.

NCT07404345 is registered in ClinicalTrials.gov with Hospital Civil de Guadalajara as lead sponsor.

NCT NCT07404345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemodialysis Catheters: A Randomized, PROBE, Parallel-Grupo Trial.
Lead sponsor
Hospital Civil de Guadalajara
Phase
Phase 4
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
September 1, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis access failure, hemodialysis catheter, kidney disease, end-stage